An exploratory study evaluating the effects of the Muscular Acoustic Modulator (MAM) on a single patient with AHC. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12493932/
This exploratory study evaluated the effects of the Muscular Acoustic Modulator (MAM) on a single patient with AHC treated for one year. The treatment was associated with a notable reduction in the frequency and duration of hemiplegic and dystonic episodes, with partial and total hemiplegic episodes decreasing by 52% and 85%, respectively, and partial dystonic episodes decreasing by 81%. Additionally, improvements in behavioral symptoms such as anger and strength outbursts were observed. We hypothesize that MAM treatment could modulate cerebrospinal fluid dynamics and enhance glymphatic drainage, potentially offering a new therapeutic approach for AHC and other neurodegenerative diseases. However, the study’s limitations, including the single-patient design, necessitate further research to confirm these preliminary results and elucidate the underlying mechanisms.
